The government will invest 520 billion won in the development of core biotechnology next year.
The Ministry of Science, ICT and ICT announced on the 22nd that it will be pushing forward with the original technology development project in the Dobio field next year to secure global technological competitiveness in the bio field, a future growth industry.
The Ministry of Science and ICT said, “Due to Corona 19, the importance of biotechnology for realizing a safe social system is increasing.” “As a new industry that will lead the future economy, the need to foster the bio industry is increasing more than ever.”
“Accordingly, next year, we decided to invest 520 billion won in the bio-sourced technology field, an increase of 24.9% compared to the previous year,” he said. Said.
The bio industry is a new industry that has a higher global market size than Korea’s three major export industries (semiconductors, automobiles, and chemicals) and has a high employment-inducing effect and job creation potential, and R&D is a success or failure of the business due to the long-term and high cost of R&D. As such, the Ministry of Science and ICT explained that it is important to make preemptive and strategic investments that consider the market and social environment.
■ Large-scale R&D intensive support for key industries such as new drugs and medical devices
The government is investing heavily in large-scale R&D in the fields of new drugs, medical devices, and regenerative medicine to foster a core bio industry that will drive future economic growth.
In the field of new drug development, we provide intensive support for the initial stages of development such as discovery and verification of new drug targets, and derivation of candidate substances, and support KRW 56 billion for the development of new drug development base technologies such as a new drug development platform using AI and the establishment of next-generation drug evaluation.
Next year, we will invest 15 billion won newly to promote the development of innovative new drugs through support for the entire life cycle of new drug development with a joint ministry.
In the medical device field, we focus on the development of new convergent medical devices such as artificial intelligence and robots with high market growth potential, while developing premium medical devices targeting the global market and developing medical devices for the disabled and the elderly to realize medical welfare. Invest 61.8 billion won to support
In addition, it plans to provide 31.1 billion won to secure technological competitiveness in the advanced regenerative medicine field, which has a high potential for future growth as it is possible to cure a fundamental disease.
The plan is to reinforce basic and mechanism research using ganoids and dedifferentiated stem cells, and to newly promote a cross-ministerial project that provides full-cycle support from core source technologies in regenerative medicine to clinical.
■ Creation of research and utilization ecosystem → Creation of future technological innovation
The government plans to support securing common core technologies that will lead to future technological innovation, and to proactively secure promising technologies in the green and white bio fields.
In order to preemptively secure four common core technologies such as microbiome, synthetic biology, bio-imaging, and single cell analysis, the company will support 51.3 billion won for the development of next-generation bio technologies, including a new investment of 5.2 billion won next year.
In addition, 27.1 billion won will be provided to the future promising green and white bio fields such as the development of new bio materials, research on biodegradable bioplastics, and the development of innovative products based on natural products.
It will also expand investments to create bio-research and utilization ecosystem.
By investing 90.3 billion won in the field of life research resources next year, we will expand the national infrastructure for self-sufficiency of bio research materials and promote the establishment of an ecosystem to foster bio data as a strategic resource.
We will support 42.3 billion won next year in the field of technology commercialization and start-up R&D so that innovative bio technologies can be linked to companies and lead to market performance. We plan to newly support intermediary research that links the results of basic research on diseases to diagnosis, treatment and prevention.
■ Infectious disease and aging response technology development
The government plans to promote the development of core technologies for infectious diseases, dementia, and brain diseases, which are closely related to people’s lives, to contribute to the establishment of a safe social system and to support the promotion of public health.
We will support 31.7 billion won to secure basic and source technologies to reinforce the capacity to respond to new and mutant infectious diseases, and to develop COVID-19 treatments and vaccines with excellent efficacy, especially next year to secure infectious disease platform technology that can be quickly applied in the event of an infectious disease crisis. Invest 10.2 billion won.
To prepare for an aging society and to lay the foundation for a healthy and happy life, we will provide KRW 53.3 billion to secure core brain technologies such as brain disease research and future brain fusion research through ICT convergence.
In addition, it invests 7.9 billion won to develop technologies for early diagnosis and preventive treatment, starting from the discovery of the cause of dementia, to help reduce the burden of dementia.
Related Articles
Vice-Chairman Seung-Joon Kim, Vice Chairman of Bio-Nano Convergence Technology, Vice-Chairman of OECD Bio-Nano Convergence Technology Working Group
KHNP promotes biogas-based hydrogen convergence project
Seoul Bio provides’Biorez’ for free to Soho Plant
New CEO of Samsung Biologics, “Leap as the world’s No. 1 biopharmaceutical company within 10 years”
The announcement of this new project will be held for one month from the 23rd to January 22nd of next year. Details can be found at
Bong-soo Kim, Director of Basic Source Research Policy, said, “Biotechnology competitiveness is becoming an essential element for a healthy and safe society beyond the core element of the national future economic development.” “The Ministry of Science and ICT is the future core technology to secure global competitiveness in biotechnology. “We will continue to provide support so that excellent source technologies developed in universities and research centers can be linked to companies and lead to market performance.”